
Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
2025 Amyloidosis Forum Annual Meeting
Wednesday, October 22, 2025
Registration Coming Soon!
Participants including clinicians, researchers, FDA and global health authorities, industry partners, patients, and the Amyloidosis Research Consortium (ARC) will detail the Amyloidosis Forum stakeholder working groups’ projects to accelerate drug development in AL and ATTR Amyloidosis.